Evicenter
P&T meetings

Azetukalner (XEN1101)

Focal onset seizures

Regulatory submission
NDA submitted September 2026
Launch
Not announced
Last updated
163 sources

Product information and disease descriptionPlace of product in therapy

Approaches to treatment

114 evidence topics · 87 sources

Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.